Radioactive tracer could supercharge cancer immunotherapy
NCT ID NCT07197671
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 39 times
Summary
This early-stage study tests a radioactive imaging agent called Y-NM600 in up to 60 people with metastatic cancer who are already on immunotherapy drugs (anti-PD-1 or anti-PD-L1). The main goals are to check safety and find the best dose, and to see if the agent can make the immunotherapy work better. Participants will be followed for up to 9 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.